MacroGenics (MGNX) News Today → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free MGNX Stock Alerts $4.09 -0.15 (-3.54%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30 at 6:10 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXMay 29, 2024 | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 29, 2024 | marketbeat.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Moderate Buy" by BrokeragesMacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the compMay 28, 2024 | stockhouse.comLost Money on MacroGenics, Inc.(MGNX)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationMay 27, 2024 | markets.businessinsider.comLevi & Korsinsky Reminds MacroGenics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - MGNXMay 26, 2024 | americanbankingnews.comMacroGenics (NASDAQ:MGNX) PT Lowered to $9.00May 25, 2024 | markets.businessinsider.comMGNX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of MacroGenics, Inc. Shareholders Who Lost MoneyMay 25, 2024 | benzinga.comMacrogenics Stock (NASDAQ:MGNX), Analyst Ratings, Price Targets, PredictionsMay 25, 2024 | investorplace.com3 Biotech Stocks That Could Be Millionaire-Makers: May EditionMay 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Iovance Biotherapeutics (IOVA)May 24, 2024 | markets.businessinsider.comDemystifying Macrogenics: Insights From 14 Analyst ReviewsMay 24, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) Given New $9.00 Price Target at BTIG ResearchBTIG Research cut their target price on MacroGenics from $24.00 to $9.00 and set a "buy" rating for the company in a research report on Friday.May 24, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: MacroGenics (MGNX) and Medtronic (MDT)May 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXMay 17, 2024 | baystreet.caPancreatic Cancer Battle Intensifies with Biotech Sector's Advanced TreatmentsMay 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXMay 15, 2024 | marketbeat.comResearch Analysts Set Expectations for MacroGenics, Inc.'s Q2 2024 Earnings (NASDAQ:MGNX)MacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Analysts at HC Wainwright decreased their Q2 2024 earnings estimates for shares of MacroGenics in a research note issued on Monday, May 13th. HC Wainwright analyst R. Burns now forecasts that the biopharmaceutical company will post earnings of ($0.7May 14, 2024 | prnewswire.comINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the FirmMay 14, 2024 | marketbeat.comQ1 2025 Earnings Estimate for MacroGenics, Inc. (NASDAQ:MGNX) Issued By HC WainwrightMacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of MacroGenics in a research report issued to clients and investors on Monday, May 13th. HC Wainwright analyst R. Burns expects that the biopharmaceutiMay 13, 2024 | markets.businessinsider.comHold Rating on MacroGenics Amid Safety and Efficacy Concerns for Vobra DuoMay 13, 2024 | tmcnet.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against MacroGenics, Inc. (MGNX)May 13, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) PT Lowered to $4.00 at HC WainwrightHC Wainwright reduced their price objective on shares of MacroGenics from $16.00 to $4.00 and set a "neutral" rating on the stock in a research report on Monday.May 13, 2024 | globenewswire.comMacroGenics to Participate in Upcoming Investor ConferencesMay 13, 2024 | seekingalpha.comMacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)May 12, 2024 | finance.yahoo.comUS$15.10: That's What Analysts Think MacroGenics, Inc. (NASDAQ:MGNX) Is Worth After Its Latest ResultsMay 11, 2024 | wsj.comMacrogenics Inc.May 11, 2024 | msn.comBMO Capital Downgrades MacroGenics (MGNX)May 10, 2024 | marketbeat.comBarclays Trims MacroGenics (NASDAQ:MGNX) Target Price to $14.00Barclays cut their price target on MacroGenics from $25.00 to $14.00 and set an "overweight" rating on the stock in a research report on Friday.May 10, 2024 | msn.comMacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'May 10, 2024 | msn.comStifel Downgrades MacroGenics (MGNX)May 10, 2024 | finance.yahoo.comMacroGenics, Inc. (NASDAQ:MGNX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comMacrogenics Inc (MGNX) Q1 2024 Earnings: Misses Revenue Estimates Amidst Ongoing Clinical ...May 10, 2024 | marketwatch.comMacroGenics Shares Plummet After Study Data Reveal Patient DeathsMay 10, 2024 | msn.comMacroGenics crashes after mid-stage data for prostate cancer drugMay 10, 2024 | investorplace.comWhy Is Macrogenics (MGNX) Stock Down 69% Today?May 10, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) Stock Rating Lowered by BMO Capital MarketsBMO Capital Markets lowered shares of MacroGenics from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $24.00 to $8.00 in a report on Friday.May 10, 2024 | finanznachrichten.deMacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study DataMay 10, 2024 | markets.businessinsider.comHold Rating on MacroGenics Amid TAMARACK Study Results and Competitive ConcernsMay 10, 2024 | markets.businessinsider.comBuy Rating on MacroGenics: Promising Clinical Data and Market Position in mCRPC TreatmentMay 10, 2024 | fool.comMacroGenics (MGNX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | msn.comMGNX Stock Earnings: Macrogenics Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comMacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study DataMay 8, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) Shares Down 10.8% MacroGenics (NASDAQ:MGNX) Shares Down 10.8%May 4, 2024 | marketbeat.comMacroGenics (MGNX) Scheduled to Post Quarterly Earnings on ThursdayMacroGenics (NASDAQ:MGNX) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 3, 2024 | finance.yahoo.comMacroGenics Announces Date of First Quarter 2024 Financial Results Conference CallMay 1, 2024 | theglobeandmail.comBiotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050April 28, 2024 | marketbeat.comMacroGenics, Inc. (NASDAQ:MGNX) Short Interest UpdateMacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 8,600,000 shares, a growth of 33.3% from the March 31st total of 6,450,000 shares. Currently, 14.7% of the company's stock are sold short. Based on an average daily trading volume, of 1,540,000 shares, the short-interest ratio is presently 5.6 days.April 26, 2024 | marketbeat.comB. Riley Begins Coverage on MacroGenics (NASDAQ:MGNX)B. Riley initiated coverage on shares of MacroGenics in a report on Friday. They set a "buy" rating and a $25.00 price target on the stock.April 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for MacroGenics on Strong Oncology Pipeline and Positive Phase II Trial ResultsApril 25, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) Trading Down 9%MacroGenics (NASDAQ:MGNX) Stock Price Down 9% Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address The only financial event in 2024 that matters (Ad)Man Who Predicted 2008 Crash Warns of Black Swan Financial Event in 2024 Porter Stansberry’s new documentary is going viral. Stream the documentary for free by clicking here MGNX Media Mentions By Week MGNX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MGNX News Sentiment▼0.190.76▲Average Medical News Sentiment MGNX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MGNX Articles This Week▼63▲MGNX Articles Average Week Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: XBiotech News Foghorn Therapeutics News Enanta Pharmaceuticals News Emergent BioSolutions News Rani Therapeutics News ESSA Pharma News 23andMe News CorMedix News Atai Life Sciences News Pyxis Oncology News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MGNX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
